GST (Gefitinib as Salvage Treatment) in Pretreated Head and Neck Squamous Cell Cancer

Faraz Khan, Manas Dubey, Rajeev Atri, Vivek Kaushal, Rakesh Dhankhar, Anil Kr Dhull
2019 Journal of Cancer Science and Clinical Therapeutics  
Purpose: To determine the efficacy and safety profiles of GST (gefitinib as salavage therapy) in patients with advanced recurrent, residual and/or metastatic squamous cell cancer of the head and neck (HNSCC). Subjects and Methods: Patients with recurrent, residual, or metastatic (R/R/M) HNSCC, were treated with gefitinib 250mg orally daily for 3 weeks. Results and Conclusion: Partial response (PR) was noted in 10% of patients, median progression free survival (PFS) was 3.3 months. Anemia was
more » ... nths. Anemia was observed in 16.7% of patients, toxicity related to total leucocyte count grade I,II &III toxicities were observed in 20%, 3.3% and 0%. Only grade I hepatic toxicity was observed in 20%. No case of renal toxicity was seen. Grade I-II upper gastrointestinal toxicity (nausea/ vomiting) was noted in 13.3% patients. Lower gastrointestinal toxicity (diarrhea) was observed in 46.7% of patients. Skin rash was graded and 8 (26.7%) patients demonstrated skin reactions. Overall survival (OS) was 4 months. Gefitinib was well tolerated in this heavily pretreated HNSCC population and produced prolonged disease stabilization.
doi:10.26502/jcsct.5079015 fatcat:y75y5vfn4vfalkyd3lhvpgyhsi